Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.
Cytotoxic activity of most chemotherapeutic agents is based on their ability to induce DNA damage. Interstrand crosslinks are among the most detrimental forms of DNA damage as both DNA strands are affected. As translesion polymerases participate in their repair, they may be important for response to chemotherapeutic agents that induce such lesions, including commonly used cisplatin. Altered expression of translesion polymerase genes REV1 and REV3L may modify sensitivity to cisplatin. As osteosarcoma patients are commonly treated with cisplatin-based chemotherapy, our aim was to investigate if REV1 and REV3L polymorphisms influence survival of osteosarcoma patients treated with cisplatin-based chemotherapy. We determined the genotypes of common functional tag REV1 and REV3L polymorphisms in 66 osteosarcoma patients. Cox regression was used for survival analysis. Carriers of at least one polymorphic REV1 rs3087403 allele had significantly shorter EFS and overall survival (OS) (p = 0.004; HR = 3.79; 95%CI = 1.53-9.35 and p < 0.001; HR = 4.44; 95%CI = 1.92-10.27, respectively). Combination of REV1 rs3087403 and REV3L rs462779 polymorphisms was also significantly associated with shorter OS (ptrend<0.001) and shorter EFS (ptrend = 0.003). The results of this first study on polymorphisms in translesion polymerase genes in osteosarcoma suggest they could help predict outcome of cisplatin-based chemotherapy in osteosarcoma patients.
1 Pharmacogenetics Laboratory, Institute of Biochemistry , Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia .
Katja
K
Goričar
Viljem
V
Kovač
Janez
J
Jazbec
Branko
B
Zakotnik
Janez
J
Lamovec
Vita
V
Dolžan
D000293:Adolescent; D000328:Adult; D000483:Alleles; D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics; D004259:DNA-Directed DNA Polymerase / Q000235:genetics; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D009687:Nuclear Proteins / Q000235:genetics; D009713:Nucleotidyltransferases / Q000235:genetics*; D016017:Odds Ratio; D012516:Osteosarcoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D011110:Polymorphism, Genetic; D011379:Prognosis; D016019:Survival Analysis; D055815:Young Adult; D000099270:Y-Family DNA Polymerases
D004268:DNA-Binding Proteins; D004259:DNA-Directed DNA Polymerase; D009687:Nuclear Proteins; D009713:Nucleotidyltransferases; C429004:REV1 protein, human; D000099270:Y-Family DNA Polymerases; C118285:REV3L protein, human